First Bancorp emerges from its Q2 earnings report with analysts nudging targets higher yet remaining split on conviction — a setup that captures the stock's current ambiguity perfectly.
The most recent analyst action came this morning. Piper Sandler's Stephen Scouten raised his target to $65 from $64 while holding a Neutral rating — a token lift that keeps the stock essentially at fair value in his view. Raymond James took a sharper stance two weeks ago, lifting to $75 from $68 and maintaining Strong Buy. Those two moves frame the debate clearly: bulls see room for a further 15-17% from current levels around $64.22, while the more cautious contingent thinks the stock is already close to fully priced. The consensus mean target of $68.80 implies about 7% upside. The bull case rests on loan growth recovery and NIM expansion; the bear case points to potential credit deterioration in First Bancorp's core markets. On valuation, the stock trades at 13.1x earnings and 1.4x book — both broadly stable over the past month, suggesting the re-rating from earnings has been modest rather than dramatic.
Options positioning has locked in at the extreme bullish end since Q2 results dropped. The put/call ratio has barely moved from 0.025 all week — essentially unchanged from the pre-earnings reading flagged in our July 23 note, and still close to the 52-week floor of zero. That ratio runs nearly 1.4 standard deviations below its 20-day mean of 1.97. The consistency of the signal is notable: this is not a brief spike but a sustained tilt toward calls that has held through the post-earnings session. Meanwhile the lending market is relaxed. Short interest eased 2.4% on the week to just under 4.9% of free float, borrow costs dipped to 0.44%, and availability is generous at 444% — meaning roughly four shares sit available to borrow for every one already lent out, well above the 52-week trough of 387%. No squeeze pressure is building here.
The stock itself rose 2.6% on the day to $64.22 but is marginally negative on the week, down 0.4%. Close peers moved more decisively: UBSI gained 3.8% on the week and CPF added 1.6%, while COLB dropped 4.8%. FBNC's flat weekly performance against a broadly firmer peer group suggests the post-earnings bounce has been contained rather than broad-based. The Q2 print itself produced a 1-day move of roughly -1.9%, extending a recent pattern of muted negative reactions — the April print also closed down about 1.1% the following day.
Insider activity adds a note of caution to the otherwise bullish options tone. The CFO, CEO, and a senior officer all sold shares on June 29, collectively disposing of around 10,800 shares near $63.50. A director sold 44,000 shares in May at $58.58 — the largest single transaction in the recent window. Net insider selling over the past 90 days totals roughly $3.3 million. None of the individual transactions carry high significance scores, suggesting routine scheduled selling rather than conviction-driven exits, but the direction is uniformly one way.
The next scheduled earnings date is October 23. Between now and then, the key question is whether the NIM expansion thesis — the central pillar of the bull case — shows up in loan book data before analysts revisit targets again. The ORTEX short score has eased from 55.8 two weeks ago to 53.3 today, a modest retreat that reflects the slight reduction in short positioning, and whether that softening continues will be worth tracking alongside any credit-quality updates from management.
See the live data behind this article on ORTEX.
Open FBNC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
